ロード中...
Which are the antibodies to watch in 2013?
The start of the new year signals that it is time for mAbs’ annual review of the therapeutic monoclonal antibodies (mAbs) in active Phase 2/3 or Phase 3 clinical studies. The entire clinical pipeline currently includes ~350 mAbs, but most of these are in early development. As of the beginning of 201...
保存先:
| 第一著者: | |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Landes Bioscience
2013
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3564874/ https://ncbi.nlm.nih.gov/pubmed/23254906 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/mabs.22976 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|